Results 31 to 40 of about 400 (115)

A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (µ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty

Journal of Pain Research, 2017
Oliceridine (TRV130), a novel μ-receptor G-protein pathway selective (μ-GPS) modulator, was designed to improve the therapeutic window of conventional opioids by activating G-protein signaling while causing low β-arrestin recruitment to the μ receptor.
Singla,Neil, Minkowitz,Harold, Soergel,David, Burt,David, Subach,Ruth Ann, Salamea,Monica, Fossler,Michael, Skobieranda,Franck   +7 more
openaire   +4 more sources

Poorly controlled postoperative pain: prevalence, consequences, and prevention

Journal of Pain Research, 2017
Tong J Gan Stony Brook University, Stony Brook, NY, USA Abstract: This review provides an overview of the clinical issue of poorly controlled postoperative pain and therapeutic approaches that may help to address this common unresolved health-care ...
Gan TJ
doaj  

<p>APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the &micro;-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy</p>

Journal of Pain Research, 2019
Oliceridine is a novel G protein-biased µ-opioid receptor agonist designed to provide intravenous (IV) analgesia with a lower risk of opioid-related adverse events (ORAEs) than conventional opioids.APOLLO-1 (NCT02815709) was a phase III, double-blind, randomized trial in patients with moderate-to-severe pain following bunionectomy.
Eugene R Viscusi, Franck Skobieranda, David G Soergel, Emily Cook, David A Burt, Neil Singla   +5 more
openaire   +5 more sources

APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy

Journal of Pain Research, 2019
Eugene R Viscusi,1 Franck Skobieranda,2 David G Soergel,2 Emily Cook,2 David A Burt,2 Neil Singla3 1Department of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA; 2Trevena Inc., Chesterbrook, PA, USA ...
Viscusi ER, Skobieranda F, Soergel DG, Cook E, Burt DA, Singla N   +5 more
doaj  

Additional file 1 of TRV130 inhibits colon cancer progression via suppressing the Hedgehog signaling pathway: in vitro and in vivo evidence

Supplementary Material 1.
Zhuang, Yuanzhao, Jiang, Changcheng, Guo, Yuqing, Sun, Jiaxiao   +3 more
openaire   +1 more source

Additional file 2 of TRV130 inhibits colon cancer progression via suppressing the Hedgehog signaling pathway: in vitro and in vivo evidence

Supplementary Material 2.
Zhuang, Yuanzhao, Jiang, Changcheng, Guo, Yuqing, Sun, Jiaxiao   +3 more
openaire   +1 more source

A Bibliometric and Visual Analysis of Oliceridine Research (2013–2024)

Drug Design, Development and Therapy
Cheng Song,1,* Xinxing Huang,2,* Nianping Chen,1 Qiliang Song,3 Yuanli Qiu1 1Department of Anesthesiology, Affiliated Hospital of Shaoxing University, Zhejiang, 312000, People’s Republic of China; 2Department of Anesthesiology, Jinhua Maternal ...
Song C, Huang X, Chen N, Song Q, Qiu Y
doaj  

IUPHAR themed review: Opioid efficacy, bias, and selectivity. [PDF]

Pharmacol Res, 2023
Ramos-Gonzalez N, Paul B, Majumdar S.
europepmc   +1 more source

Targeting Opioid Receptors in Addiction and Drug Withdrawal: Where Are We Going? [PDF]

Int J Mol Sci, 2023
Tabanelli R, Brogi S, Calderone V.
europepmc   +1 more source

Pharmacological Advances in Opioid Therapy: A Review of the Role of Oliceridine in Pain Management. [PDF]

Pain Ther, 2021
Kaye AD, Edinoff AN, Babin KC, Hebert CM, Hardin JL, Cornett EM, Kaye AJ, Kaye AM, Urman RD.   +8 more
europepmc   +1 more source